NCT04365543

Brief Summary

If someone is really sensitive to certain noises and sounds, they might have misophonia. U-HEAR is a study created to find out what helps kids and teens with misophonia. There are two treatments being tested in this study. The treatment your child receives will be determined at random. There will be a Two-Thirds (2/3rds or 66%) chance your child will receive a treatment called the Unified Protocol for Children and Adolescents (UP-C/A) that has been modified to meet the needs for youth with misophonia. There is a One-Third (1/3rd or 33%) chance your child will receive a treatment called Psychoeducation and Relaxation. All participants will get ten free treatment sessions. Each session will last one hour and happen once a week. The aim of the study is to evaluate the feasibility and preliminary efficacy of the UP-C/A for youth with misophonia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
124

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2020

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 8, 2020

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

April 22, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 28, 2020

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

April 28, 2020

Status Verified

April 1, 2020

Enrollment Period

1.9 years

First QC Date

April 22, 2020

Last Update Submit

April 27, 2020

Conditions

Keywords

misophoniasensory sensitivityanxietysound

Outcome Measures

Primary Outcomes (8)

  • Improvement in symptoms measured by Clinical Global Impression - Improvement (5 weeks)

    Clinical Global Impression-Improvement (CGI-I) is a 7-point clinician rated scale of treatment response anchored by 1 (very much improved) and 7 (very much worse). For categorical secondary outcomes, response is defined as a CGI-I rating of 1 or 2 (much improved/very much improved), and remission as CGI-S of 1 to 2. CGI-I will be used to measure symptom improvement after 5 weeks of treatment.

    5 weeks

  • Improvement in symptoms measured by Clinical Global Impression - Improvement (10 weeks)

    Clinical Global Impression-Improvement (CGI-I) is a 7-point clinician rated scale of treatment response anchored by 1 (very much improved) and 7 (very much worse). For categorical secondary outcomes, response is defined as a CGI-I rating of 1 or 2 (much improved/very much improved), and remission as CGI-S of 1 to 2. CGI-I will be used to measure symptom improvement after 10 weeks of treatment.

    10 weeks

  • Severity of symptoms measured by Clinical Global Impression - Severity (Baseline)

    Clinical Global Impression-Severity (CGI-S) is a widely used 7-point clinician rating of severity of psychopathology; raters will be instructed to score based on psychopathology and misophonia symptoms. Severity ratings range from 1 (no illness) to 7 (extremely severe). Severity will be measured before treatment begins to create a baseline for each participant.

    Baseline

  • Severity of symptoms measured by Clinical Global Impression - Severity (5 weeks)

    Clinical Global Impression-Severity (CGI-S) is a widely used 7-point clinician rating of severity of psychopathology; raters will be instructed to score based on psychopathology and misophonia symptoms. Severity ratings range from 1 (no illness) to 7 (extremely severe). CGI-S will be used to measure severity after 5 weeks of treatment.

    5 weeks

  • Severity of symptoms measured by Clinical Global Impression - Severity (10 weeks)

    Clinical Global Impression-Severity (CGI-S) is a widely used 7-point clinician rating of severity of psychopathology; raters will be instructed to score based on psychopathology and misophonia symptoms. Severity ratings range from 1 (no illness) to 7 (extremely severe). CGI-S will be used to measure severity after 10 weeks of treatment.

    5 weeks

  • Overall impairment measured by Child's Global Assessment Scale (Baseline)

    Clinician rated measure of general functioning including impairment to capture functioning/impairment independent of diagnoses. The child or young person is given a single score between 1 and 100, based on a clinician's assessment of a range of aspects related to a child's psychological and social functioning. The score will put them in one of ten categories that range from 'extremely impaired' (1-10) to 'doing very well' (91-100. General functioning of the participant will be measured before treatment begins to create a baseline for each subject.

    Baseline

  • Overall impairment measured by Child's Global Assessment Scale (5 weeks)

    Clinician rated measure of general functioning including impairment to capture functioning/impairment independent of diagnoses. The child or young person is given a single score between 1 and 100, based on a clinician's assessment of a range of aspects related to a child's psychological and social functioning. The score will put them in one of ten categories that range from 'extremely impaired' (1-10) to 'doing very well' (91-100). CGAS will be used to measure general functioning after 5 weeks of treatment.

    5 weeks

  • Overall impairment measured by Child's Global Assessment Scale (10 weeks)

    Clinician rated measure of general functioning including impairment to capture functioning/impairment independent of diagnoses. The child or young person is given a single score between 1 and 100, based on a clinician's assessment of a range of aspects related to a child's psychological and social functioning. The score will put them in one of ten categories that range from 'extremely impaired' (1-10) to 'doing very well' (91-100). CGAS will be used to measure general functioning after 10 weeks of treatment.

    10 weeks

Secondary Outcomes (6)

  • Misophonia symptoms as measured by Misophonia Assessment Questionnaire

    Baseline

  • Change in misophonia symptoms as measured by Misophonia Assessment Questionnaire

    5 weeks

  • Change in misophonia symptoms as measured by Misophonia Assessment Questionnaire

    10 weeks

  • Misophonia symptoms as measured by Misophonia Questionnaire

    Baseline

  • Change in misophonia symptoms as measured by Misophonia Questionnaire

    5 weeks

  • +1 more secondary outcomes

Study Arms (2)

UP-C/A for Misophonia

EXPERIMENTAL

The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) are manualized treatments for treating emotional disorders in youth. We have modified the UP-C/A to meet the needs for youth with misophonia.

Behavioral: Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia

Psychoeducation and Relaxation Therapy

EXPERIMENTAL

Psychoeducation and Relaxation Therapy (PRT) is a treatment that educates the child on misophonia and provides training in relaxation skills and tools for calming panic, anxiety and anger feelings.

Behavioral: Psychoeducation and Relaxation Therapy (PRT)

Interventions

Please see arm/group descriptions

Psychoeducation and Relaxation Therapy

Eligibility Criteria

Age8 Years - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • The child meets criteria for misophonia
  • The child is currently living with their family/guardian(s)
  • The child is between 8 and 16 years old
  • Parent/legal guardian and child are able to read and speak English without a translator
  • Parent/legal guardian is able to attend weekly sessions and all assessments
  • If the child is on a psychotropic medication, they will need to be on a stable dose for 4 weeks prior to assessment (2 weeks for stimulant medication)

You may not qualify if:

  • The child has received prior UP-C/A treatment
  • The child is acutely suicidal
  • The child has a current diagnosis of psychosis, bipolar disorder, intellectual disability, alcohol/substance dependence, or eating disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Child and Adolescent Mood and Anxiety Treatment (CAMAT) Program at the University of Miami

Coral Gables, Florida, 33124, United States

RECRUITING

University of Florida Rothman Center

St. Petersburg, Florida, 33701, United States

RECRUITING

MeSH Terms

Conditions

misophoniaAnxiety Disorders

Interventions

Relaxation Therapy

Condition Hierarchy (Ancestors)

Mental Disorders

Intervention Hierarchy (Ancestors)

Mind-Body TherapiesComplementary TherapiesTherapeuticsBehavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Adam Lewin, PhD

    University of South Florida

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kelly Kudryk, BA

CONTACT

Jane Mutch, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor and Interim Division Chief

Study Record Dates

First Submitted

April 22, 2020

First Posted

April 28, 2020

Study Start

April 8, 2020

Primary Completion

March 1, 2022

Study Completion

December 1, 2022

Last Updated

April 28, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will share

The sponsor requests de-identified data as a grant requirement in order to better the understand of misophonia. At the conclusion of the study, we will provide the de-identified data.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Approximately 2 years following the completion of the analyses. Duration of the availability is at Sponsor's discretion.
Access Criteria
Access is at Sponsor's discretion.

Locations